₹ 3,501.37 Cr
2.11%
BSE Healthcare TRI
INF179KC1HM5
100.0
100.0
100
Nikhil Mathur, Bhagyesh Kagalkar
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| HDFC Pharma And Healthcare Fund - IDCW Option | 19.93 | 28.22 | - |
| Benchmark | - | - | - |
Equity
Debt
Others
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
| Company | Holdings (%) |
|---|---|
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 9.39 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 8.28 |
| TREPS - Tri-party Repo | 4.67 |
| ALKEM LABORATORIES LIMITED EQ | 4.64 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 4.15 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 3.69 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 3.65 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 3.61 |
| ASTER DM HEALTHCARE LIMITED EQ | 3.56 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 3.55 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 95.76 |
| Consumer Services | 1.01 |
| Scheme Name | 5Y (%) |
|---|---|
| HDFC Pharma And Healthcare Fund IDCW | 0.0 |